- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07449702
Eine offene Verlängerungsstudie von ORKA-001 bei Teilnehmern mit Plaque-Psoriasis
Eine offene Verlängerungsstudie zur Bewertung der langfristigen Sicherheit, Verträglichkeit und Wirksamkeit von ORKA-001 bei Teilnehmern mit mittelschwerer bis schwerer Plaque-Psoriasis
An open-label extension (OLE) study to evaluate the long-term safety and efficacy of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis, who previously participated in an Oruka Therapeutics sponsored study.
Studienübersicht
Detaillierte Beschreibung
This open-label extension study evaluates the long-term safety and efficacy of ORKA-001 in adults with moderate-to-severe plaque psoriasis. The study includes an open-label treatment period of up to approximately 96 weeks and a post-treatment follow-up period of approximately 48 weeks following the last study visit.
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 2
Kontakte und Standorte
Studienkontakt
- Name: Oruka Clinical Trials Information
- Telefonnummer: 781-560-0299
- E-Mail: clinicaltrials@orukatx.com
Studienorte
-
-
Alberta
-
Edmonton, Alberta, Kanada, T5J 3S9
- Rekrutierung
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-Mail: clinicaltrials@orukatx.com
-
Edmonton, Alberta, Kanada, T6G 1C3
- Rekrutierung
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-Mail: clinicaltrials@orukatx.com
-
-
British Columbia
-
Surrey, British Columbia, Kanada, V3R 6A7
- Rekrutierung
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-Mail: clinicaltrials@orukatx.com
-
Surrey, British Columbia, Kanada, V3V 0C6
- Rekrutierung
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Therapeutics Investigative Site
- Telefonnummer: 781-560-0299
- E-Mail: clinicaltrials@orukatx.com
-
-
New Brunswick
-
Fredericton, New Brunswick, Kanada, E3B IG9
- Rekrutierung
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-Mail: clinicaltrials@orukatx.com
-
-
Ontario
-
Ajax, Ontario, Kanada, L1S7K8
- Rekrutierung
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Therapeutics Investigative Site
- Telefonnummer: 781-560-0299
- E-Mail: clinicaltrials@orukatx.com
-
London, Ontario, Kanada, N6H 5L5
- Rekrutierung
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-Mail: clinicaltrials@orukatx.com
-
Markham, Ontario, Kanada, L3P 1X3
- Rekrutierung
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-Mail: clinicaltrials@orukatx.com
-
Peterborough, Ontario, Kanada, K9J 5K2
- Rekrutierung
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-Mail: clinicaltrials@orukatx.com
-
Toronto, Ontario, Kanada, M4W 2N4
- Rekrutierung
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-Mail: clinicaltrials@orukatx.com
-
Waterloo, Ontario, Kanada, N2J 1C4
- Rekrutierung
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-Mail: clinicaltrials@orukatx.com
-
-
Quebec
-
Montreal, Quebec, Kanada, H2X2V1
- Rekrutierung
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Therapeutics Investigative Site
- Telefonnummer: 781-560-0299
- E-Mail: clinicaltrials@orukatx.com
-
Québec, Quebec, Kanada, G1V4X7
- Rekrutierung
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Therapeutics Investigative Site
- Telefonnummer: 781-560-0299
- E-Mail: clinicaltrials@orukatx.com
-
-
-
-
Arizona
-
Phoenix, Arizona, Vereinigte Staaten, 85032
- Rekrutierung
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Therapeutics Investigative Site
- Telefonnummer: 781-560-0299
- E-Mail: clinicaltrials@orukatx.com
-
-
Arkansas
-
North Little Rock, Arkansas, Vereinigte Staaten, 72117
- Rekrutierung
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-Mail: clinicaltrials@orukatx.com
-
-
California
-
Fountain Valley, California, Vereinigte Staaten, 92708
- Rekrutierung
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-Mail: clinicaltrials@orukatx.com
-
Los Angeles, California, Vereinigte Staaten, 90045
- Rekrutierung
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-Mail: clinicaltrials@orukatx.com
-
Los Angeles, California, Vereinigte Staaten, 90095
- Rekrutierung
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-Mail: clinicaltrials@orukatx.com
-
San Diego, California, Vereinigte Staaten, 92123
- Rekrutierung
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-Mail: clinicaltrials@orukatx.com
-
Santa Ana, California, Vereinigte Staaten, 92701
- Rekrutierung
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-Mail: clinicaltrials@orukatx.com
-
Santa Monica, California, Vereinigte Staaten, 90403
- Rekrutierung
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-Mail: clinicaltrials@orukatx.com
-
-
Connecticut
-
Cromwell, Connecticut, Vereinigte Staaten, 06416
- Rekrutierung
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-Mail: clinicaltrials@orukatx.com
-
-
Florida
-
Miami, Florida, Vereinigte Staaten, 33126
- Rekrutierung
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-Mail: clinicaltrials@orukatx.com
-
-
Illinois
-
Rolling Meadows, Illinois, Vereinigte Staaten, 60008
- Rekrutierung
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-Mail: clinicaltrials@orukatx.com
-
-
Indiana
-
Plainfield, Indiana, Vereinigte Staaten, 46168
- Rekrutierung
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-Mail: clinicaltrials@orukatx.com
-
-
Kentucky
-
Bowling Green, Kentucky, Vereinigte Staaten, 42104
- Rekrutierung
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- E-Mail: clinicaltrials@orukatx.com
-
-
Maryland
-
Rockville, Maryland, Vereinigte Staaten, 20850
- Rekrutierung
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-Mail: clinicaltrials@orukatx.com
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02111
- Rekrutierung
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-Mail: clinicaltrials@orukatx.com
-
-
Michigan
-
Detroit, Michigan, Vereinigte Staaten, 48202
- Rekrutierung
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-Mail: clinicaltrials@orukatx.com
-
-
New York
-
New York, New York, Vereinigte Staaten, 10023
- Rekrutierung
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-Mail: clinicaltrials@orukatx.com
-
New York, New York, Vereinigte Staaten, 10029
- Rekrutierung
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-Mail: clinicaltrials@orukatx.com
-
-
Ohio
-
Cleveland, Ohio, Vereinigte Staaten, 44106
- Rekrutierung
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-Mail: clinicaltrials@orukatx.com
-
Mason, Ohio, Vereinigte Staaten, 45040
- Rekrutierung
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Therapeutics Investigative Site
- Telefonnummer: 781-560-0299
- E-Mail: clinicaltrials@orukatx.com
-
-
Oregon
-
Portland, Oregon, Vereinigte Staaten, 97201
- Rekrutierung
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-Mail: clinicaltrials@orukatx.com
-
Portland, Oregon, Vereinigte Staaten, 97210
- Rekrutierung
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-Mail: clinicaltrials@orukatx.com
-
-
Texas
-
Frisco, Texas, Vereinigte Staaten, 75033
- Rekrutierung
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Therapeutics Investigative Site
- Telefonnummer: 781-560-0299
- E-Mail: clinicaltrials@orukatx.com
-
Houston, Texas, Vereinigte Staaten, 77004
- Rekrutierung
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-Mail: clinicaltrials@orukatx.com
-
Webster, Texas, Vereinigte Staaten, 77598
- Rekrutierung
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Therapeutics Investigative Site
- Telefonnummer: 781-560-0299
- E-Mail: clinicaltrials@orukatx.com
-
-
Virginia
-
Norfolk, Virginia, Vereinigte Staaten, 23502
- Rekrutierung
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-Mail: clinicaltrials@orukatx.com
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Signed informed consent by participants from previous trial choosing to transition into the OLE.
- Participants who have successfully completed the preceding trial.
- For women of childbearing potential, must have a negative urine pregnancy test at Baseline visit.
- For women of childbearing potential and fertile male participants with a partner of childbearing potential must be willing to continue to use highly effective contraception
Exclusion Criteria:
- Participants who experienced any adverse events with ORKA-001 in the preceding trial that led to permanent investigational medicinal product discontinuation or, in the opinion of the Investigator, would preclude continued treatment with ORKA-001
- Participants who have developed guttate, erythrodermic or pustular psoriasis or drug-induced psoriasis (as diagnosed by the Investigator), during the preceding trial.
- Evidence of current or previous clinically significant disease, medical condition other than psoriasis, or finding during the medical examination that, in the opinion of the Investigator would compromise the safety of the participant or the quality of the data.
- Any clinically significant laboratory abnormality based on the last available lab results received during the preceding trial, that, according to the Investigator's medical assessment, precludes them from continued treatment with ORKA-001.
- Participant is pregnant or breastfeeding.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: ORKA-001 Once Yearly (High Dose)
Participants will receive ORKA-001 once a year per OLE protocol. |
ORKA-001 administered by subcutaneous (SC) injection |
|
Experimental: ORKA-001 Once Yearly (Low Dose)
Participants will receive ORKA-001 once a year per OLE protocol. |
ORKA-001 administered by subcutaneous (SC) injection |
|
Experimental: ORKA-001 Twice Yearly
Participants will receive ORKA-001 every 6 months per OLE protocol. |
ORKA-001 administered by subcutaneous (SC) injection |
|
Kein Eingriff: No Drug
Participants will receive no drug until protocol defined PASI response criterion is met. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Incidence of Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and TEAEs of Special Interest (TEAESIs)
Zeitfenster: Day 1 through Week 144
|
Incidence of treatment adverse events, treatment-emergent serious adverse events, treatment adverse events of special interest, and potential clinically significant changes from baseline in vital signs, clinical laboratory parameters and electrocardiograms. |
Day 1 through Week 144
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Proportion of Participants Maintaining PASI100 in the Subset of Participants Meeting the Criterion at Baseline of OLE
Zeitfenster: Day 1 through Week 96
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Day 1 through Week 96
|
|
Proportion of Participants Maintaining PASI90 in the Subset of Participants Meeting the Criterion at Baseline of OLE
Zeitfenster: Day 1 through Week 96
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Day 1 through Week 96
|
|
Proportion of Participants Maintaining Investigator's Global Assessment (IGA) 0 in the Subset of Participants Meeting the Criterion at Baseline of OLE
Zeitfenster: Day 1 through Week 96
|
The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). |
Day 1 through Week 96
|
|
Proportion of Participants Maintaining Investigator's Global Assessment (IGA) 0/1 in the Subset of Participants Meeting the Criterion at Baseline of OLE
Zeitfenster: Time Frame: Day 1 through Week 96
|
The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). |
Time Frame: Day 1 through Week 96
|
|
Proportion of Participants with an Improvement of their OLE Baseline PASI Score in the Subset of Participants who did not Achieve PASI75 at OLE Baseline
Zeitfenster: Day 1 through Week 96
|
Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Day 1 through Week 96
|
|
Time-to-loss of PASI100 in the Subset of Participants who achieved PASI100 at Baseline of OLE
Zeitfenster: Day 1 through Week 96
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Day 1 through Week 96
|
|
Time-to-loss of PASI90 in the Subset of Participants who achieved PASI90 at Baseline of the OLE
Zeitfenster: Day 1 through Week 96
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Day 1 through Week 96
|
|
PASI Score Over Time
Zeitfenster: Day 1 through Week 96
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Day 1 through Week 96
|
|
IGA Score Over Time
Zeitfenster: Day 1 through Week 96
|
The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). |
Day 1 through Week 96
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Andere Studien-ID-Nummern
- ORKA-001-113
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .